^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ICOSLG (Inducible T Cell Costimulator Ligand)

    i
    Other names: ICOSLG, Inducible T Cell Costimulator Ligand, B7RP-1, B7-H2, B7RP1, B7H2, B7-Related Protein 1, B7 Homolog 2, KIAA0653, ICOS-L, CD275, ICOSL, GL50, B7h, B7-Like Protein Gl50, B7 Homologue 2, ICOS Ligand, Transmembrane Protein B7-H2 ICOS Ligand, Inducible T-Cell Costimulator Ligand, CD275 Antigen, LICOS
    26d
    Utility of a Digital PCR-Based Gene Expression Panel for Detection of Leukemic Cells in Pediatric Acute Lymphoblastic Leukemia. (PubMed, Int J Mol Sci)
    While the panel showed promising performance for distinguishing MRD-positive from MRD-negative samples, the limited MRD-positive cohort size (n = 11) indicates that validation in larger MRD-focused studies is required before clinical implementation for treatment monitoring. This dPCR-based platform provides accessible, quantitative detection without requiring knowledge of clonal shifts or specific genomic landscape, offering potential advantages for resource-limited settings such as those represented in our Mexican pediatric cohort.
    Journal
    |
    PTK7 (Protein Tyrosine Kinase 7) • ICOSLG (Inducible T Cell Costimulator Ligand) • GATA3 (GATA binding protein 3) • SNAI1 (Snail Family Transcriptional Repressor 1)
    3ms
    Construction of a prognostic model for nasopharyngeal carcinoma based on serum exosomal circular RNAs and analysis of immune microenvironment. (PubMed, Clin Exp Med)
    Additionally, immune checkpoint gene analysis revealed significantly higher expression of CD276 and ICOSLG in the high-risk group compared to the low-risk group. Our findings suggest that serum exosomal circRNAs may be promising prognostic biomarkers in NPC, warranting further functional and clinical validation.
    Journal
    |
    CD276 (CD276 Molecule) • CD4 (CD4 Molecule) • ICOSLG (Inducible T Cell Costimulator Ligand)
    3ms
    CST7+ macrophages/monocytes in melanoma: single-cell insights into immunotherapy response. (PubMed, Transl Cancer Res)
    These findings suggest that CST7+ macrophages/monocytes are associated with immunotherapy response by correlating with cytotoxic T-cell activation through the ICOSL/ICOS pathway. The observed interaction highlights the potential for combining immune checkpoint inhibitors (ICIs) with ICOS/ICOSL agonistic antibodies to enhance and sustain long-term immunotherapy efficacy in patients with melanoma.
    Journal • IO biomarker
    |
    ICOS (Inducible T Cell Costimulator) • ICOSLG (Inducible T Cell Costimulator Ligand)
    4ms
    Malignant cell-mediated Treg immune suppression via ICOSLG-ICOS axis in tumor microenvironment relates to nasopharyngeal carcinoma prognosis. (PubMed, Int Immunopharmacol)
    These findings were further corroborated by our single-cell RNA data and multiplex immunohistochemistry results, which provided additional substantiation for the observed interactions. These observations regarding the interaction between the tumor microenvironment and nasopharyngeal carcinoma have significant clinical implications for the future treatment of NPC.
    Journal
    |
    TNFRSF17 (TNF Receptor Superfamily Member 17) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • ICOS (Inducible T Cell Costimulator) • ICOSLG (Inducible T Cell Costimulator Ligand) • TNFRSF4 (TNF Receptor Superfamily Member 4) • CD48 (CD48 Molecule) • OASL (2'-5'-Oligoadenylate Synthetase Like) • CD80 (CD80 Molecule)
    4ms
    Targeting heat shock protein 90 with usnic acid relieves immune suppression via aryl hydrocarbon receptor-mediated mechanisms in lung cancer. (PubMed, Mol Biomed)
    In addition, KU decreased the proliferation marker, antigen Kiel 67 (Ki67⁺), and HSP90⁺ cell populations within tumors. Together, these findings demonstrate that UA/KU targets the HSP90-AhR axis, suppresses immune evasion pathways, and offers a novel immunomodulatory approach for lung cancer therapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • ICOS (Inducible T Cell Costimulator) • ICOSLG (Inducible T Cell Costimulator Ligand)
    4ms
    Deciphering tumor-intrinsic and immune characteristics in resectable non-small cell lung cancer treated with neoadjuvant pembrolizumab and chemotherapy. (PubMed, J Transl Med)
    Our study identified molecular biomarkers for pathological and survival outcomes, which may inform optimal treatment decision-making, guide postoperative therapy, and improve survival outcomes for stage II-III patients with resectable NSCLC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • B2M (Beta-2-microglobulin) • HMGB1 (High Mobility Group Box 1) • HLA-E (Major Histocompatibility Complex, Class I, E) • ICOSLG (Inducible T Cell Costimulator Ligand) • CEACAM6 (CEA Cell Adhesion Molecule 6) • BTN3A1 (Butyrophilin Subfamily 3 Member A1) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Keytruda (pembrolizumab)
    5ms
    Soluble immune checkpoint factors reveal high-risk osteosarcoma subtypes and enable early metastasis prediction. (PubMed, Front Immunol)
    Using peripheral blood biomarkers, we characterized immune subtypes of osteosarcoma, and developed a predictive model for metastasis. These biomarkers may serve as potential therapeutic targets for future immunotherapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • S100A8 (S100 Calcium Binding Protein A8) • ICOSLG (Inducible T Cell Costimulator Ligand) • TNFRSF4 (TNF Receptor Superfamily Member 4) • HHLA2 (HERV-H LTR-Associating 2) • NCR3LG1 (Natural Killer Cell Cytotoxicity Receptor 3 Ligand 1) • CD48 (CD48 Molecule) • VSIR (V-Set Immunoregulatory Receptor)
    7ms
    Comprehensive Characterization of the Immune Microenvironment Based on Nested Resampling Machine Learning Framework Identifies TRAF3 Interacting Protein 3 as a Promising Regulator to Improve the Resistance to Immunotherapy in Glioma. (PubMed, Adv Sci (Weinh))
    Through single-cell analysis of published and in-house datasets, TRAF3IP3 exhibited selective enrichment in NPC-like and MES-like tumor cells, and showed a dual functionality in mediating T-Cell Exhaustion. Targeting TRAF3IP3 emerges as a promising avenue to combat immunotherapy resistance, particularly in glioma, thus paving the way for precision medicine.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TNFAIP3 (TNF Alpha Induced Protein 3) • CCL19 (C-C Motif Chemokine Ligand 19) • ICOSLG (Inducible T Cell Costimulator Ligand)
    |
    PD-L1 expression
    10ms
    Multiplex immunophenotyping of human acute myeloid leukemia patients revealed single -cell heterogeneity with special attention on therapy sensitive and therapy resistant subpopulations. (PubMed, Front Immunol)
    This study focused on understanding the LAIP in AML before and after therapeutic intervention. The study highlights the potential of using single-cell LAIP profiling and immune mediator measurements to monitor therapy response and identify measurable residual disease and therapy resistant cell populations in AML.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • IL2RA (Interleukin 2 receptor, alpha) • CD33 (CD33 Molecule) • CD34 (CD34 molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • ICOSLG (Inducible T Cell Costimulator Ligand) • CD7 (CD7 Molecule)
    11ms
    Identification of Recurrence-associated Gene Signatures and Machine Learning-based Prediction in IDH-Wildtype Histological Glioblastoma. (PubMed, J Mol Neurosci)
    Machine learning analysis demonstrated that random forest (RF) was the most effective model, achieving AUC values of 0.998, 0.968, and 0.998 in the training, CGGA-693 validation, and CGGA-325 validation cohorts, respectively, suggesting high predictive accuracy. This study identifies novel recurrence-associated molecular signatures and establishes a machine learning-based predictive model in IDH-wildtype histological GBM.
    Journal • Gene Signature
    |
    ICOSLG (Inducible T Cell Costimulator Ligand)
    |
    IDH wild-type
    11ms
    Identification of lncRNAs in peripheral blood mononuclear cells associated with sepsis immunosuppression based on weighted gene co-expression network analysis. (PubMed, Hereditas)
     Our findings highlight novel lncRNA-regulated pathways in sepsis-induced immunosuppression, providing potential targets for improved diagnosis and therapy.
    Journal • IO biomarker
    |
    ICOS (Inducible T Cell Costimulator) • ICOSLG (Inducible T Cell Costimulator Ligand) • IKZF2 (IKAROS family zinc finger 2)
    11ms
    The Immune Environment in Colorectal Adenoma: A Systematic Review. (PubMed, Biomedicines)
    The over-expression of COX-2, PD-1/PD-L1, CTLA-4, and ICOS/ICOSLG in the colorectal adenomatous and cancerous tissues was also observed. Further studies are needed for a better understanding of the whole picture of colorectal adenoma-associated immunity and its impact on precancerous lesion's potential to progress.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule) • ICOS (Inducible T Cell Costimulator) • IL10 (Interleukin 10) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • ICOSLG (Inducible T Cell Costimulator Ligand) • IL18 (Interleukin 18) • TGFB1 (Transforming Growth Factor Beta 1) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • IL21 (Interleukin 21) • IL4 (Interleukin 4) • IL33 (Interleukin 33)